ノースカロライナにおけるバーキットリンパ腫の臨床試験
ノースカロライナ内の拠点で、バーキットリンパ腫に関する13件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 他2件
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- East Carolina University, Greenville
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第3相
18歳〜39歳 · 全性別 · 2026/10/02更新 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Wake Forest University Health Sciences, Winston-Salem
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- 他2件
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 他3件
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 他4件
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Levine Children's Hospital, Charlotte
被験者募集中第2相
7歳〜25歳 · 全性別 · 2026/08/19更新 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- 他4件
被験者募集中観察研究
65歳以上 · 全性別 · 2026/06/29更新 · NCT01137825Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2025/10/27更新 · NCT01137643The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Atrium Health - Levine Cancer Center, Charlotte
被験者募集中第2相
1歳〜25歳 · 全性別 · 2025/05/04更新 · NCT03509961ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。